A Public Option for Clinical Trials? Lessons from Convalescent Plasma.

IF 1.6 4区哲学 Q2 ETHICS

Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI:10.1017/jme.2024.57

Victor Roy, Joseph S Ross, Reshma Ramachandran

引用次数: 0

Abstract

The case of clinical trials for convalescent plasma during COVID-19 illustrates important lessons for realizing public sector approaches to biomedical research and development. These lessons, centering on mission, transparency, and spillover effects, can be translated to wider efforts to develop a "public option" for clinical trials.

查看原文本刊更多论文

临床试验的公共选择？从康复血浆中汲取的教训。

COVID-19 期间的疗养血浆临床试验案例为公共部门实现生物医学研究与发展提供了重要经验。这些经验教训以使命、透明度和溢出效应为中心，可以转化为更广泛的努力，为临床试验提供 "公共选择"。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Law Medicine & Ethics 医学-医学：法

CiteScore

2.90

自引率

4.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Material published in The Journal of Law, Medicine & Ethics (JLME) contributes to the educational mission of The American Society of Law, Medicine & Ethics, covering public health, health disparities, patient safety and quality of care, and biomedical science and research. It provides articles on such timely topics as health care quality and access, managed care, pain relief, genetics, child/maternal health, reproductive health, informed consent, assisted dying, ethics committees, HIV/AIDS, and public health. Symposium issues review significant policy developments, health law court decisions, and books.